Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India

Clinical Infectious Diseases

Volumn 56, Issue 8, 2013, Pages 1123-1131

  Ali, Mohammad ^a   Sur, Dipika ^b   You, Young Ae ^a   Kanungo, Suman ^b   Sah, Binod ^a   Manna, Byomkesh ^b   Puri, Mahesh ^a   Wierzba, Thomas F ^a   Donner, Allan ^c   Nair, G Balakrish ^b   Bhattacharya, Sujit K ^d   Dhingra, Mandeep Singh ^e   Deen, Jacqueline L ^f   Lopez, Anna Lena ^a,g   Clemens, John ^a,h  

^a International Vaccine Institute   (South Korea)

^b NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d SOCIETY FOR APPLIED STUDIES   (India)

^e Shantha Biotechnics Limited   (India)

^f MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^g UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bivalent killed oral cholera vaccine; cholera; cluster randomized trial; herd effect

Indexed keywords

CHOLERA VACCINE; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM ISOLATION; CHILD; CHOLERA; COMPARATIVE STUDY; CONTROLLED STUDY; DYSENTERY; FEMALE; GEOGRAPHIC INFORMATION SYSTEM; HAZARD RATIO; HERD IMMUNITY; HUMAN; INCIDENCE; INDIA; INFANT; MAJOR CLINICAL STUDY; MALE; NEIGHBORHOOD; PHASE 3 CLINICAL TRIAL; POPULATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RESIDENT; SCHOOL CHILD; VIBRIO CHOLERAE; WHOLE CELL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHOLERA; CHOLERA VACCINES; CLUSTER ANALYSIS; HUMANS; IMMUNITY, HERD; INDIA; INFANT; POVERTY AREAS; PROPORTIONAL HAZARDS MODELS; RISK; TREATMENT OUTCOME; URBAN POPULATION; VACCINATION; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84875640885     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit009     Document Type: Article

References (32)

1. Clemens J, Shin S, Ali M. New approaches to the assessment of vaccine herd protection in vaccine trials. Lancet Infect Dis 2011; 11:482-7.
2. Whitney C, Farley M, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46. (Pubitemid 36514704)
3. Preziosi M, Yam A, Wassilak S, et al. Epidemiology of pertussis in a West African community before and after introduction of a widespread vaccination program. Am J Epidemiol 2002; 155:891-6. (Pubitemid 34517844)
4. McVernon J, Ramsay M, McLean A. Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom. Epidemiol Infect 2008; 136:800-12. (Pubitemid 351524015)
5. Trollfors B, Taranger J, Lagergard T, et al. Immunization of children with pertussis toxoid decreases spread of pertussis with the family. Pediatr Infect Dis J 1998; 17:196-9. (Pubitemid 28146059)
6. Schlenker T, Baine C, Baaughman A, Hadler S. Measles herd immunity. The association of attack rates with immunization rates in preschool children. JAMA 1992; 267:823-6.
7. Fox J. Herd immunity and measles. J Infect Dis 1983; 5:463-6.
8. Black F. The role of herd immunity in the control of measles. Yale J Biol Med 1982; 55:351-60. (Pubitemid 13119670)
9. Miller LW, Older J, Drake J, Zimmerman S. Diphtheria immunization: effect upon carriers and the control of outbreaks. Am J Dis Child 1972; 123:197-9.
10. Trotter C, Edmunds W. Re-assessing the cost-effectiveness of meningococcal serogroup C conjugate (MDD) vaccines using a transmission dynamic model. Med Decis Making 2006; 26:39-47.
11. Longini I, Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD. Controlling endemic cholera with oral vaccines. PLoS Med 2007; 4:e336.
12. Halloran ME, Struchiner CJ, Longini IM Jr. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997; 146:789-803. (Pubitemid 27498097)
13. Hayes RJ, Alexander ND, Bennet S, Cousens SN. Design and analysis issues in cluster-randomised trials of interventions against infectious diseases. Stat Methods Med Res 2009; 9:95-116.
14. Donner A, Klar N. Design and analysis of cluster randomization trials in health research. London, UK: Arnold, 2000.
15. Ali M, Emch M, von Seidlein L, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005; 366:44-9. (Pubitemid 40956529)
16. Sur D, Lopez AL, Kanungo S, et al. Field trial of a locally produced, bivalent killed whole cell oral cholera vaccine in India. Lancet 2009; 374:1694-702.
17. Sur D, Kanungo S, Sah B, et al. Efficacy of a low-cost, killed whole-cell oral cholera vaccine: results from 3 years of follow up of a clusterrandomized, placebo-controlled trial. PLoS Negl Trop Dis 2011; 5:e1289.
18. Ali M, Park JK, Thiem VD, Canh DG, Emch M, Clemens JD. Neighborhood size and local geographic variation of health and social determinants. Int J Health Geographics 2005; 4:12.
19. World Health Organization. The treatment of diarrhea: a manual for physicians and other senior health workers, 4th revision. Geneva, Switzerland: WHO, 2005.
20. Halloran ME, Longini Jr. IM Struchiner CJ. Design and analysis of vaccine studies. New York: Springer, 2009.
21. Lucas M, Deen JL, von Seidlein L, et al. High-level effectiveness of a mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005; 352:757-67. (Pubitemid 40271170)
22. Lin D, Wei L. The robust inference for the proportional hazards model. J Am Statist Assoc 1989; 84:1074-8.
23. Reid N, Crepeau H. Influence functions for proportional hazards regression. Biometrika 1985; 172:1-9.
24. Lee EW, Wei LJ, Amato DA. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: Survival analysis: state of the art. Ed. JP Klein, PK Goel. Dordrecht, The Netherlands: Kluwer Academic, 1992:237-47.
25. Agresti A. Categorical data analysis. Hoboken, New Jersey: John Wiley & Sons, 2002:181-2.
26. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986; 2:124-7. (Pubitemid 16098257)
27. John TJ, Samuel R. Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol 2000; 16:601-6.
28. Clemens JD, Sack DA, van Loon FPL, et al. Non-participation as a determinant of adverse health outcomes in a field trial of oral cholera vaccines. Am J Epidemiol 1992; 135:865-74.
29. Khatib AM, Ali M, von Seidlein L, et al. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect Dis 2012; 12:837-44.
30. Médicins Sans Frontières (Doctors Without Borders). Vaccinating against cholera in Guinea: a promising approach to outbreak response. Available at: http://www.doctorswithoutborders.org/press/release.cfm? id=6051&cat=press-release. Accessed 12 September 2012.
31. Knox R. Vaccination against cholera finally begins In Haiti. Available at: http://www.npr.org/blogs/health/2012/04/12/150493770/vaccinationagainst- cholera-finally-begins-in-haiti. Accessed 12 September 2012.
32. World Health Organization. Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 2010; 85:117-28.